Stallion India Fluorochemicals Reports Robust Q2 & H1 FY25-26 Results, Details Strategic Expansions
Stallion India Fluorochemicals reported strong Q2 and H1 FY25-26 results with significant revenue and profit growth. The company detailed strategic CapEx plans for R32 manufacturing, HFO, specialty gases, and semiconductor/helium processing, targeting 30-35% CAGR.
The announcement details strong financial performance, indicating robust business growth. Significant capital expenditure plans for backward integration (R32 plant), expansion into HFO refrigerants, specialty gases, and high-purity semiconductor gases, along with a positive long-term growth outlook and market positioning, suggest a high potential impact on the company's future operations, profitability, and market share.
The company reported substantial year-on-year growth in revenue, EBITDA, and PAT for both Q2 and H1 FY25-26, exceeding 50% of its full-year revenue guidance. Management expressed confidence in achieving future growth targets and expects margin enhancement from strategic integration and expansion plans.
Stallion India Fluorochemicals Limited has released the transcript of its Investor Conference held on 15 October 2025, discussing the company's business and financial performance for the quarter and half year ended 30 September 2025.
* Financial Highlights for Q2 FY25-26: * Total revenues stood at ₹105.75 crore, marking a solid 55.6% year-on-year (YoY) growth. * EBITDA surged nearly seven-fold to ₹15.77 crore, with margins expanding to 14.9%. * Profit After Tax (PAT) increased to ₹11.42 crore. * Financial Highlights for H1 FY25-26: * Total revenue reached ₹216.3 crore, representing a 52.8% YoY growth. * EBITDA for the period almost doubled to ₹13.14 crore. * PAT increased by 135% to ₹21.78 crore.
Management noted that over 50% of the full-year revenue guidance of ₹430 crore has already been achieved in the first half. They expressed confidence in achieving growth targets for FY25-26, as the second half is traditionally stronger for the business. The company targets a 30-35% CAGR growth over the next three years, with backward and forward integration initiatives expected to enhance operating margins by 3-4%.
Strategic Initiatives and Capex: * Bhilwara, Rajasthan Facility: A 10,000 metric ton R32 manufacturing facility is under development, providing backward integration for critical raw material. This project is expected to be completed in 9 months (by July 2026) with a minimum CapEx requirement of ₹200 crore, plus working capital. * Mambattu, Andhra Pradesh Facility: The fifth operational site is being enhanced to expand blending and debulking capacity for HFO refrigerants and specialty gases, and to add semiconductor and helium-processing capabilities. The project scope has been increased 2.5 times, with the CapEx for enhancement rising from ₹20 crore to ₹30 crore, funded by internal accruals. Commissioning is now anticipated by January end or February 2026. * Khalapur Facility: Expansion is underway to strengthen capabilities in liquid helium and high-purity semiconductor gases, targeting India's emerging electronic, solar, and fiber optic industries. The CapEx for this expansion is approximately ₹30 crore.
During the Q&A session, discussions included the future HFC quota system expected in 2028 (with modalities in 2027), the tradability of these quotas, and the specialized handling and processing of helium gas for high-purity applications like semiconductors. The company emphasized its strategic entry into semiconductor gases due to India's self-reliance push, the segment's profitability, and the diversification it offers against cyclical product demand.
What to do with a filing like this
Stallion India Fluorochemicals Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Stallion India Fluorochemicals Limited. Read the original for the full detail.